Population pharmacokinetic meta-analysis of individual data to design the first randomized efficacy trial of vancomycin in neonates and young infants

Jacqz-Aigrain, Evelyne and Leroux, Stéphanie and Thomson, Alison H. and Allegaert, Karel and Capparelli, Edmund V. and Biran, Valérie and Simon, Nicolas and Meibohm, Bernd and Lo, Yoke-Lin and Marques, Remedios and Peris, José-Esteban and Lutsar, Irja and Saito, Jumpei and Nakamura, Hidefumi and van den Anker, Johannes N. and Sharland, Mike and Zhao, Wei (2019) Population pharmacokinetic meta-analysis of individual data to design the first randomized efficacy trial of vancomycin in neonates and young infants. Journal of Antimicrobial Chemotherapy, 74 (8). pp. 2128-2138. ISSN 0305-7453 (https://doi.org/10.1093/jac/dkz158)

[thumbnail of Jacqz-Aigrain-etal-JAC-2019-randomized-efficacy-trial-of-vancomycin-in-neonates-and-young-iInfantss]
Preview
 Text. Filename: Jacqz_Aigrain_etal_JAC_2019_randomized_efficacy_trial_of_vancomycin_in_neonates_and_young_iInfantss.pdf
Accepted Author Manuscript
Download (2MB)| Preview

Abstract

OBJECTIVES: In the absence of consensus, the present meta-analysis was performed to determine an optimal dosing regimen of vancomycin for neonates. METHODS: A 'meta-model' with 4894 concentrations from 1631 neonates was built using NONMEM, and Monte Carlo simulations were performed to design an optimal intermittent infusion, aiming to reach a target AUC0-24 of 400 mg·h/L at steady-state in at least 80% of neonates. RESULTS: A two-compartment model best fitted the data. Current weight, postmenstrual age (PMA) and serum creatinine were the significant covariates for CL. After model validation, simulations showed that a loading dose (25 mg/kg) and a maintenance dose (15 mg/kg q12h if <35 weeks PMA and 15 mg/kg q8h if ≥35 weeks PMA) achieved the AUC0-24 target earlier than a standard 'Blue Book' dosage regimen in >89% of the treated patients. CONCLUSIONS: The results of a population meta-analysis of vancomycin data have been used to develop a new dosing regimen for neonatal use and to assist in the design of the model-based, multinational European trial, NeoVanc.

ORCID iDs

Jacqz-Aigrain, Evelyne, Leroux, Stéphanie, Thomson, Alison H. ORCID logoORCID: https://orcid.org/0000-0002-2354-6116, Allegaert, Karel, Capparelli, Edmund V., Biran, Valérie, Simon, Nicolas, Meibohm, Bernd, Lo, Yoke-Lin, Marques, Remedios, Peris, José-Esteban, Lutsar, Irja, Saito, Jumpei, Nakamura, Hidefumi, van den Anker, Johannes N., Sharland, Mike and Zhao, Wei;
CORE (COnnecting REpositories)